Tuesday, November 16; 8:30am – 5:00pm
Dr. Matthew Blatnik, Pfizer, Groton, CT
Dr. Graham West, Pfizer, Groton, CT
This introductory course is designed to teach participants the utility, advantages, and limitations of conducting LC-MSn analysis using high resolution mass spectrometers. We will cover a wide range of introductory topics from how do we introduce/create ions, what is high resolution and accurate mass to walking through several qualitative and quantitative workflows. We dive into the differences between mass analyzers (e.g. sectors, quads, trap, TOF, Orbi and FTICR) and how these technologies along with their limitations have evolved into what are today’s HRMS systems.
WHO SHOULD ATTEND
Individuals who are new to HRMS, do not have a complete understanding of the differences between mass analyzers and mass filters and want a better foundation to understanding, using or purchasing HRMS platforms in their workflows.
1. Fundamental Concepts for HRMS
a. Mass terminology
b. Mass separation
c. Mass measurement
d. Mass defect
2. Instrument Types and Concepts
a. Quadrupole and ion trap
b. Time of flight (TOF)
c. Fourier transform ion cyclotron resonance (FTICR)
a. Mass resolution
b. Scan speed
c. Options for fragmentation (HCD, CID, CAD, ETS, etc.)
4. Qualitative Analysis
a. HRMS for structural elucidation
b. Interpretation of elemental composition
c. Data mining
5. Quantitative Analysis
a. Key variables in HRMS quantitation
6. Quan-Qual Workflows
a. Instrument options
b. Instrument limitations
d. Third party software
ABOUT THE INSTRUCTORS:
Dr. Matthew Blatnik earned his Ph.D. in Biochemistry from The University of South Carolina under the supervision of John W. Baynes and Caryn C. Outten at The University of South Carolina. After graduate school he accepted a GLP small molecule position with Pfizer Inc. in 2008. After deciding, relatively fast that small molecule GLP wasn’t for him, he moved into a discovery biomarker bioanalysis role. After 12 years at Pfizer, he is currently the precision medicine mass spectrometry lab head for Pfizer’s Early Clinical Development organization. He and his team develop novel strategies and assays to interpret the biological effects of therapeutic intervention in human patients using mass spectrometry-based technologies. Some of his mass spectrometry work has contributed to novel findings published in Nature Medicine, Cell Biology and JCRI to name a few. Matt’s professional activities outside of Pfizer include speaking engagements, teaching short courses and squeezing in workouts to flex his biceps along with his brain.
Dr. Graham West received his B.S. in Chemistry at North Carolina State University (Raleigh, NC) and PhD in the Fitzgerald lab at Duke University where he designed and applied mass spectrometry-based technologies to characterize protein-ligand interactions. He then pioneered the application of HDX to GPCRs during his postdoc studies in Professor Patrick Griffin’s lab at the Scripps Research Institute, Florida. Dr West’s industrial career has included positions with the Research Triangle Institute and Novartis, and he is currently at Pfizer. His lab at Pfizer uses protein biochemistry, NMR and mass spectrometry to advance the early stage R&D portfolio. He has authored over 30 publications in the field of mass spectrometry.